Liquid biopsy is a minimally invasive test that detects cancer by analyzing tumor-derived materials—such as circulating tumor DNA (ctDNA) or cells—present in the blood. It can identify genetic mutations, monitor treatment response, and sometimes detect cancer earlier than traditional tissue biopsies, though its accuracy can vary depending on cancer type and stage. While it offers advantages like reduced discomfort and the ability to track tumor changes over time, it may not fully replace conventional biopsies for diagnosis. Considering liquid biopsy for screening, monitoring, or guiding treatment decisions should involve a discussion with your oncologist to understand its benefits, limitations, and suitability for your specific situation.